

14-541ACL: Claudin18.2/HEK293 Stable Cell Line

Application : Functional Assay

Description

Claudin 18.2/HEK293 Stable Cell Line is a stably transfected HEK293 cell line which expresses human claudin 18.2 (CLDN18.2). CLDN18.2 is a highly selective marker protein that is exclusively expressed in differentiated gastric mucosal membrane epithelial cells. Abnormal expression of CLDN18.2 has been observed during the occurrence and development of various primary malignant tumors such as gastric cancer, breast cancer, colon cancer and liver cancer. CLDN18.2 has become a significant biomarker for targeted therapy in different cancers, and a monoclonal antibody against CLDN18.2 such as Anti-CLDN18.2 (zolbetuximab biosimilar, Abeomics, Cat. No.: 12-9134) is an example utilized in the immunotherapy targeting CLDN18.2.

Sequence data: Human CLDN18.2 (accession number NP_001002026)

MAVTACQGLGFVSLIGIAGIIAATCMDQWSTQDLYNNPVTAVFNYYQGLWRSCVRESSGFTECRGYFTLLGLPAM
LQAVRALMIVGIVLGAIGLLVSIFALKCIRIGSMEDSAKANMTLTSGIMFIVSGLCAIAGVSVFANMLVTNFWMSTA
NMYTGMGGMVQTVQTRYTFGAALFVGWVAGGLTLIGGVMMCIACRGLAPEETNYKAVSYHASGHSVAYKPGG
FKASTGFGSNTKNKKIYDGGARTEDEVQSYPSKHDYV

Product Info

Amount : 1 Vial
Content : Each vial contains $2 \sim 3 \times 10^6$ cells in 1 ml of 90% FBS + 10% DMSO
Storage condition : Immediately upon receipt, store in liquid nitrogen.

Application Note

Application:

- Screen for antibodies of human Claudin 18.2 through Flow Cytometry.

Culture conditions:

Cells should be grown at 37°C with 5% CO₂ using DMEM medium (w/ L-Glutamine, 4.5g/L Glucose and Sodium Pyruvate) supplemented with 10% heat-inactivated FBS and 1% Pen/Strep, plus 10 µg/ml of Blasticidin.

It is recommended to quickly thaw the frozen cells upon receipt or from liquid nitrogen in a 37°C water-bath, transfer to a tube containing 10 ml of growth medium without Blasticidin, spin down cells, resuspend cells in pre-warmed growth medium without Blasticidin, transfer resuspended cells to T25 flask and culture in 37°C-CO₂ incubator.

Leave the T25 flask in the incubator for 1~2 days without disturbing or changing the medium until cells completely

recover viability and become adherent. Once cells are over 90% adherent, remove growth medium and passage the cells through trypsinization and centrifugation. At first passage, switch to growth medium containing Blasticidin. Cells should be split before they reach complete confluence.

To passage the cells, detach cells from culture vessel with Trypsin/EDTA, add complete growth medium and transfer to a tube, spin down cells, resuspend cells and seed appropriate aliquots of cells suspension into new culture vessels. Subcultivation ration = 1:10 to 1:20 weekly. To achieve satisfactory results, cells should not be passaged over 16 times.

LIMITED USE RESTRICTIONS:

THIS PRODUCT IS SOLELY FOR IN VITRO RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

By use of this product, user agrees to be bound by the terms of this limited use statement.

This product is solely for Internal Research Purposes and not for Commercial Purposes. Commercial Purposes include, but are not limited to (1) use of the cell line in manufacturing; (2) use of the cell line to provide a service, information or data; (3) use of the cell line for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the cell line whether or not such cell lines are resold for use in research. The buyer cannot sell, give or otherwise transfer this product to a third party.

Commercial License Agreement is available for non-research use if applicable. Please contact Abeomics (info@abeomics.com).




Fig-1: Detection of human CLDN18.2 in the HEK293/CLDN18.2 stable cell line by flow cytometry using Anti-CLDN18.2 mAb (zolbetuximab; Abeomics, Cat. No. 12-9134) at 2 ug per 1×10^6 cells. The secondary antibody used was FITC-conjugated goat anti-human IgG, Fc-gamma (Jackson, #109-095-098). Parental HEK293 cells (Green); HEK293/CLDN18.2 (Red).